Clinical Trial Update: Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating mitomycin-C in patients with advanced or recurrent pancreatic cancer harboring a BRCA2 mutation was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Mitomycin-C (mitomycin C)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Pancreatic Cancer | Phase 2 | Status: WITHDRAWN